TherapeuticsMD reports Q3 net loss $1.4M; evaluates strategic alternatives

TherapeuticsMD, Inc.

2023-Q3 EPS reported -$0.92 vs consensus -$0.05 ▼ miss (-1703.9%)

Net loss from continuing ops $1.4M ($0.13/share) vs $14.6M ($1.58) in Q3 2022.
License and service revenue negative $0.1M; gross royalties $1.2M for quarter.
Operating expenses fell 88.2% to $1.7M on transition to royalty-based model.
Board evaluating strategic alternatives including M&A, sale, or other transaction.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TherapeuticsMD, Inc. reported the third quarter ended September 30, 2023 results: net income Net loss from continuing operations was $1.4 million for the quarter ended September 30, 2023, or $0.13 per basic and di, EPS $0.13 per basic and diluted common share.

Period: the third quarter ended September 30, 2023
Net income: Net loss from continuing operations was $1.4 million for the quarter ended September 30, 2023, or $0.13 per basic and di
EPS: $0.13 per basic and diluted common share
Result: reported results

Exact text from the filing

TherapeuticsMD Announces Third Quarter 2023 Financial Results

View on SEC.gov

Browse all earnings releases →

TherapeuticsMD, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-277136

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.